secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0000950170-24-141323
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement
--------------------------------------------------------------------------------

- Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.
- Norman Staskey appointed President, CFO and Principal Financial Officer effective Dec 30, 2024, via Danforth Advisors consulting agreement.
- Staskey is paid $450/hour under the Danforth Consulting Agreement; he also serves as CFO of Azitra, Inc.
- Staskey brings M&A experience as company pursues potential strategic transactions with other pharma firms.
- Amendment No. 6 to Consulting Agreement formalizes Staskey's services; prior CFO services were from Hess.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024141323/0000950170-24-141323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024141323/onvo-20241223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-141323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer